Sanofi-Aventis to develop MRSA vaccine with Syntiron
This article was originally published in Scrip
Executive Summary
Sanofi Pasteur, Sanofi-Aventis's vaccines division, has acquired an exclusive global licence to develop and commercialise the private US company Syntiron's prophylactic vaccine against Staphylococcus, including meticillin-resistant Staphylococcus aureus (MRSA).